Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00555204 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 2
- Development phase
- 337
- Enrollment target
NCT00555204: Clinical Trial Phase 2 study, sponsored by Abbott.
NCT00555204 is a Phase 2 study that was terminated before completion, run by Abbott. The registered enrollment target is 337 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00555204, a Phase 2 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 337 participants
- Enrollment target
Study Summary
The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.
Interventions
- DRUG ABT-089
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2007-11 |
| Phase | Phase 2 |
Why NCT00555204 stopped before completion
NCT00555204 is an interventional study that assigns participants to a tested intervention. The registered 337 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher).
The record links to 0 conditions, and to 1 intervention - of which ABT-089 is the first listed.
NCT00555204 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00555204 about?
NCT00555204 is a clinical study titled "Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease". The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.
What is the current status of trial NCT00555204?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 337 participants. The study started on 2007-11.
What interventions are being tested in trial NCT00555204?
The interventions under investigation include: ABT-089 (DRUG).
Who is sponsoring clinical trial NCT00555204?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00555204's enrollment target sits among peer trials
337 141st of 2000 higher than 1,860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia